Activated prothrombin complex concentrate for dabigatran-associated bleeding.

Abstract

A humanized antibody fragment to reverse the oral thrombin inhibitor dabigatran is currently under development (Schiele et al, 2013). The absence of a specific reversal agent has caused apprehension over the use of this anticoagulant (Cotton et al, 2011). Prothrombin complex concentrate (PCC) and activated factor VII seemed ineffective in recently reported… (More)
DOI: 10.1111/bjh.12620

Topics

2 Figures and Tables

Blog articles referencing this paper

Slides referencing similar topics